Skip to main content
    C

    Climb Bio Inc (CLYM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.78
    -0.16 (-1.61%)

    Market Cap: $583.86M

    Last updated: Nov 17, 2026 at 4:29 PM ET

    Climb Bio Inc (CLYM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Climb Bio (CLYM) has a market cap of $583.86M and an enterprise value of $544.13M. Its share count is up 17.69% from a year earlier.

    Total Valuation

    Enterprise value is 6.80% below the market cap, as cash exceeds debt.

    Market Cap$583.86M
    Enterprise Value$544.13M
    Latest price (Nov 17, 2026)$9.78

    Key Dates

    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.09% in the quarter ended Sep 30, 2026 and grew 9.28% a year over 2 years.

    Shares Outstanding80.03M
    Shares Change (YoY)+17.69%
    Shares Change (QoQ)+5.09%
    Share Count Growth (2Y CAGR)+9.28%

    Price Statistics

    The stock is up 414.74% over 52 weeks and trades 13.76% below its 50-day average.

    Beta (1Y)1.58
    52-Week Change+414.74%
    1-Month Change+0.51%
    3-Month Change-43.60%
    6-Month Change+1.35%
    5-Year Change-41.16%
    Total Return (1Y)+414.74%
    Total Return (3Y CAGR)+56.72%
    Total Return (5Y CAGR)-11.37%
    Return vs SPY (1Y)+400.48%
    Max Drawdown (1Y)-50.62%
    Max Drawdown (3Y)-88.92%
    Sharpe Ratio (1Y)1.74
    Correlation with SPY (1Y)0.23
    50-Day Average$11.34
    200-Day Average$10.72
    52-Week Range$1.64 to $18.33
    RSI (14 Days)44.1
    Average Volume (20 Days)1.28M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 26.58x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio26.58x
    Quick Ratio26.58x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -26.01% over the last 12 months, against a 5-year average of -33.67%.

    Return on Equity (ROE)-26.01%
    Return on Assets (ROA)-25.07%
    ROE (5Y Average)-33.67%
    ROA (5Y Average)-32.48%
    ROIC (5Y Average)-33.56%

    Scores

    CLYM has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit-$30.00K
    Operating Income-$66.76M
    Pretax Income-$59.31M
    Net Income-$59.31M
    Reported EPS (TTM)-$0.82

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 96.40% of the $236.56M in total assets.

    Cash and Equivalents$39.73M
    Total Debt$0
    Net Cash$39.73M
    Net Cash Per Share$0.50
    Working Capital$202.24M
    Shareholder Equity$228.05M
    Book Value Per Share$2.85
    Total Assets$236.56M
    Total Liabilities$8.51M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.08M of capital spending, operating cash flow left -$53.64M of free cash flow.

    Operating Cash Flow-$52.56M
    Capital Expenditures$1.08M
    Free Cash Flow-$53.64M
    FCF Per Share-$0.93
    Depreciation and Amortization$1.96M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-22.24%
    Tangible Book Per Share Growth (2Y CAGR)-22.24%

    Revenue and profit by year

    Dividends and Yields

    CLYM does not pay a dividend. Its free cash flow yield is -6.85%.

    FCF Yield-6.85%
    Buyback Yield-13.21%
    Shareholder Yield-13.21%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CLYM

    What is CLYM's market cap?

    Climb Bio has a market cap of $583.86M. Its enterprise value, which adds debt and subtracts cash, is $544.13M.

    How many shares of CLYM are outstanding?

    Climb Bio has 80.03M shares outstanding. The count is up 17.69% from a year earlier.

    Does CLYM pay a dividend?

    No. Climb Bio does not pay a dividend.

    How much debt does CLYM have?

    Climb Bio has $0 of total debt and $39.73M of cash and equivalents, a net cash position of $39.73M.